SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Okay. Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my team, Malcolm Kuno and Priyanka Grover.
We're going to kick the conference off with the presentation from SpringWorks. And speaking on behalf of the company, we have CEO, Saqib Islam. Saqib?
Thank you, Anupam. It's a pleasure to be here, and we appreciate you hosting us again this year. Before we begin, I'll remind you that today's presentation includes some forward-looking statements. And why don't I start on slide 3?
We're beginning an exciting and defining year for SpringWorks as we transition into a commercial-stage oncology company. We expect to have two product launches by 2025, starting with nirogacestat, our gamma secretase inhibitor for patients with desmoid tumors later this year.
We're also developing mirdametinib, our MEK inhibitor for patients with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
